%0 Journal Article
%T Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials
%A Alison Pedley
%A Anirban Basu
%A Erik R Dubberke
%A Mary Beth Dorr
%A Mary E Hanson
%A Oliver A Cornely
%A Ruifeng Xu
%A Sebastian M Heimann
%A Stephen Marcella
%A Vimalanand S Prabhu
%A Yoav Golan
%J Archive of "Open Forum Infectious Diseases".
%D 2018
%R 10.1093/ofid/ofy218
%X Patients with recurrent Clostridium difficile infection (rCDI) are more likely to have a hospital readmission and spend increased time in inpatient settings compared with patients with primary CDI. MODIFY I and II demonstrated that bezlotoxumab significantly reduced rCDI vs placebo. A post hoc within-trial analysis assessed whether bezlotoxumab was associated with a reduction in cumulative inpatient-days
%K CDI burden of disease
%K Clostridium difficile infection
%K recurrence
%K rehospitalization
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237242/